Ma P - Search Results

1

Severe intestinal barrier damage in HIV-infected immunological non-responders.

Guo XY, Guo YT, Wang ZR, Jiao YM, Hu Y, Fan LN, Cheng RQ, Qu MM, Zhang C, Song JW, Xu RN, Fan X, Xu W, Zhang JY, Bai BK, Linghu EQ, Chen YK, Ma P, Wang FS. Guo XY, et al. Among authors: ma p. Heliyon. 2023 Oct 12;9(10):e20790. doi: 10.1016/j.heliyon.2023.e20790. eCollection 2023 Oct. Heliyon. 2023. PMID: 37876458 Free PMC article.

2

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China.

Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Xia H, et al. Among authors: ma p. Front Pharmacol. 2020 May 19;11:710. doi: 10.3389/fphar.2020.00710. eCollection 2020. Front Pharmacol. 2020. PMID: 32508646 Free PMC article.

3

Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis.

Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Xia H, et al. Among authors: ma p. Ann Transl Med. 2021 May;9(10):847. doi: 10.21037/atm-21-1297. Ann Transl Med. 2021. PMID: 34164481 Free PMC article.

4

Consequences of HIV/Syphilis Co-Infection on HIV Viral Load and Immune Response to Antiretroviral Therapy.

Fan L, Yu A, Zhang D, Wang Z, Ma P. Fan L, et al. Among authors: ma p. Infect Drug Resist. 2021 Jul 24;14:2851-2862. doi: 10.2147/IDR.S320648. eCollection 2021. Infect Drug Resist. 2021. PMID: 34335031 Free PMC article.

5

P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target.

Zaongo SD, Liu Y, Harypursat V, Song F, Xia H, Ma P, Chen Y. Zaongo SD, et al. Among authors: ma p. Front Immunol. 2021 Aug 9;12:710121. doi: 10.3389/fimmu.2021.710121. eCollection 2021. Front Immunol. 2021. PMID: 34434194 Free PMC article. Review.

6

Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure.

Zaongo SD, Wang Y, Ma P, Song FZ, Chen YK. Zaongo SD, et al. Among authors: ma p. Chin Med J (Engl). 2021 Oct 7;134(23):2776-2787. doi: 10.1097/CM9.0000000000001797. Chin Med J (Engl). 2021. PMID: 34620750 Free PMC article.

7

Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.

Xia H, Huang XJ, Hu Y, Gao LY, Wu Y, Wu H, Yan ZF, Ma P. Xia H, et al. Among authors: ma p. Chin Med J (Engl). 2021 Oct 13;134(23):2850-2856. doi: 10.1097/CM9.0000000000001824. Chin Med J (Engl). 2021. PMID: 34653085 Free PMC article.

8

Characterization and distribution of HIV-infected cells in semen.

Gao L, Jiao YM, Ma P, Sun L, Zhao H, Guo AL, Fan X, Zhang C, Song JW, Zhang JY, Lu F, Wang FS. Gao L, et al. Among authors: ma p. Emerg Microbes Infect. 2022 Dec;11(1):860-872. doi: 10.1080/22221751.2022.2049982. Emerg Microbes Infect. 2022. PMID: 35253610 Free PMC article.

9

Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China.

Gao L, Xia H, Zeng R, Wu Y, Zaongo SD, Hu Y, Ma P. Gao L, et al. Among authors: ma p. HIV Med. 2022 Mar;23 Suppl 1:84-94. doi: 10.1111/hiv.13252. HIV Med. 2022. PMID: 35293099 Free article.

10

Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.

Zhong M, Chen C, Hu Y, Zou M, Yan L, Huang J, Lv R, Su Y, Qi M, Ye Z, Pei X, Ma P, Wei H. Zhong M, et al. Among authors: ma p. J Acquir Immune Defic Syndr. 2022 Oct 1;91(S1):S42-S50. doi: 10.1097/QAI.0000000000003047. J Acquir Immune Defic Syndr. 2022. PMID: 36094514

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,300 results

Search Page